The Food and Drug Administration said Wednesday it is halting any consideration of new drugs from Ranbaxy's Paonta Sahib plant, saying officials there falsified data on more than two dozen of its generic drugs submitted to the agency.
The action comes six months after the FDA closed U.S. borders to more than 30 generic drugs made at that plant and another Indian plant where inspectors uncovered manufacturing problems.
Source
No comments:
Post a Comment